Given the expanding role of GLP-1As in psychiatric treatment, including eating disorders, psychiatric pharmacists should recognize appropriate patients for this medication class and explain both its benefits and risks
Outside the central nervous system, melatonins antioxidant actions may benefit the cardiovascular system, improving endothelial function and blood pressure and immune system, reducing oxidative burst damage during inflammatory responses
These findings suggest that once-weekly subcutaneous semaglutide, when combined with lifestyle interventions, offers superior weight loss benefits in individuals with overweight or obesity compared to once-daily subcutaneous liraglutide [10]
Adherence to Therapy: Only 32% of GLP-1 users remained on therapy at the end of year one, dropping to 15% by year two
Current approaches to treating obesity include lifestyle modifications, pharmacological therapies, and endoscopic or surgical interventions [4]
Their glucose-dependent mechanism of action means they intrinsically carry a low risk of inducing hypoglycaemia